IP Library Granted Patent US 8,497,290
Granted Patent B2
US 8,497,290 · App. 12/788,634 · Granted Jul 30, 2013

Thiocolchicine derivatives, method of making and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,497,290
App. No.
12/788,634
Granted
Jul 30, 2013
Kind
B2
Abstract

Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.

Claims (20)

1. A compound according to structure (I)

wherein R is

b.) an amino acid derivative linked through the carboxylate group selected from the group consisting of alanine and tyrosine;

c.) —CH 2 —O(C═O)R 2 where R 2 is methyl, ethyl, n-propyl, isopropyl and * is in the S configuration;

d.) —C(═O)R 3 , where R 3 is pyridyl and * is in the S configuration; or

f.) —C(═O)(CH 2 ) x SO 3 R 4 where R 4 is hydrogen or C 1 -C 3 alkyl, x is 1 or 2 and * is in the S configuration;

or a pharmaceutically acceptable salt, crystalline form, non-crystalline form, or stereoisomer thereof.

2. The compound of claim 1 , wherein R is

b.) an amino acid derivative linked through the carboxylate group selected from the group consisting of alanine and tyrosine,

or a pharmaceutically acceptable salt, crystalline form, or non-crystalline form thereof.

3. The compound of claim 1 , comprising the S isomer, wherein R is

c.) —CH 2 —O(C═O)R 2 where R 2 is methyl, ethyl, n-propyl, or isopropyl,

or a pharmaceutically acceptable salt, crystalline form, or non-crystalline form thereof.

4. The compound of claim 1 , comprising the S isomer, wherein R is

d.) —C(═O)R 3 , where R 3 is pyridyl,

or a pharmaceutically acceptable salt, crystalline form, or non-crystalline form thereof.

5. The compound of claim 1 , comprising the S isomer, wherein R is

f.) —C(═O)(CH 2 ) x SO 3 R 4 where R 4 is hydrogen or C 1 -C 3 alkyl and x is 1 or 2,

or a pharmaceutically acceptable salt, crystalline form, or non-crystalline form thereof.

6. The compound of claim 1 , wherein the compound is

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2021
From: TAKEDA PHARMACEUTICALS USA, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056831/0119 →
CHANGE OF NAME Recorded Nov 30, 2012
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: MPC OLDCO, INC.
Reel/Frame 029377/0901 →
MERGER Recorded Nov 30, 2012
From: MPC OLDCO, INC.
To: MPC MERGER SUB, INC.
Reel/Frame 029380/0671 →
MERGER Recorded Nov 30, 2012
From: MPC MERGER SUB, INC.
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 029380/0855 →
RELEASE OF SECURITY INTEREST Recorded Aug 4, 2011
From: UBS AG, STAMFORD BRANCH, A SWISS BANKING INSTITUTION
To: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
Reel/Frame 026700/0882 →
SECURITY AGREEMENT Recorded Jul 13, 2010
From: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
To: UBS AG, STAMFORD BRANCH
Reel/Frame 024672/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2010
From: MANCHANDA, RAJESH
To: MUTUAL PHARMACEUTICAL COMPANY, INC.
Reel/Frame 024453/0246 →